Induction of oligodendrocyte differentiation and in vitro myelination by inhibition of Rho-associated kinase

ASN Neuro

Volumn 6, Issue 4, 2014, Pages 1-17

  Pedraza, Carlos E ^a   Taylor, Christopher ^a   Pereira, Albertina ^a   Seng, Michelle ^a   Tham, Chui Se ^a   Izrael, Michal ^b   Webb, Michael ^a  

^a EMD Serono Research Institute   (United States)

^b Kadimastem   (Israel)

Author keywords

Cytoskeletal dynamics; Human OPCs; Maturation; Myelin regeneration; Oligodendrocytes; ROCK inhibition

Indexed keywords

LYSOPHOSPHATIDYLCHOLINE; MYELIN PROTEIN; RHO KINASE; RHO KINASE INHIBITOR; SMALL INTERFERING RNA; ENZYME INHIBITOR; NERVE GROWTH FACTOR; NERVE PROTEIN;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELL MATURATION; CELL REGENERATION; CONTROLLED STUDY; EMBRYO; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPLANT; FEMALE; FLUORESCENCE MICROSCOPY; GENE SILENCING; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; MOUSE; MYELINATION; NERVE CELL DIFFERENTIATION; NEWBORN; NONHUMAN; OLIGODENDROCYTE PRECURSOR CELL; OLIGODENDROGLIA; POLYACRYLAMIDE GEL ELECTROPHORESIS; RAT; REAL TIME POLYMERASE CHAIN REACTION; REMYELINIZATION; RNA EXTRACTION; SPINAL GANGLION; STEM CELL CULTURE; WESTERN BLOTTING; ANIMAL; ANIMAL EMBRYO; BRAIN; C57BL MOUSE; CELL CULTURE; CELL DIFFERENTIATION; COCULTURE; CYTOLOGY; DRUG EFFECTS; GENETICS; GLIA; IN VITRO STUDY; METABOLISM; MYELIN SHEATH; OPTIC NERVE; PHYSIOLOGY; STEM CELL; TIME;

ANIMALS; ANIMALS, NEWBORN; BRAIN; CELL DIFFERENTIATION; CELLS, CULTURED; COCULTURE TECHNIQUES; EMBRYO, MAMMALIAN; ENZYME INHIBITORS; GANGLIA, SPINAL; HUMANS; IN VITRO TECHNIQUES; MICE; MICE, INBRED C57BL; MYELIN PROTEINS; MYELIN SHEATH; NERVE GROWTH FACTOR; NERVE TISSUE PROTEINS; NEUROGLIA; OLIGODENDROGLIA; OPTIC NERVE; RATS; RHO-ASSOCIATED KINASES; STEM CELLS; TIME FACTORS;

EID: 84904255886     PISSN: None     EISSN: 17590914     Source Type: Journal    
DOI: 10.1177/1759091414538134     Document Type: Article

References (108)

1. Amano T., Tanabe K., Eto T., Narumiya S., & Mizuno K. (2001) LIM-kinase 2 induces formation of stress fibres, focal adhesions and membrane blebs, dependent on its activation by Rho-associated kinase-catalysed phosphorylation at threonine-505. The Biochemical Journal 354: 149-159.
2. Amin E., Dubey B. N., Zhang S. C., Gremer L., Dvorsky R., Moll J. M., Ahmadian M. R. (2013) Rho-kinase: Regulation, (dys)function, and inhibition. Biological Chemistry 394: 1399-1410.
3. Armstrong R. C. (1998) Isolation and characterization of immature oligodendrocyte lineage cells. Methods 16: 282-292.
4. Barbarese E., & Pfeiffer S. E. (1981) Developmental regulation of myelin basic protein in dispersed cultures. Proceedings of the National Academy of Sciences of the United States of America 78: 1953-1957.
5. Bernard O. (2007) Lim kinases, regulators of actin dynamics. The International Journal of Biochemistry & Cell Biology 39: 1071-1076.
6. Birgbauer E., Rao T. S., & Webb M. (2004) Lysolecithin induces demyelination in vitro in a cerebellar slice culture system. Journal of Neuroscience Research 78: 157-166.
7. Birukova A. A., Smurova K., Birukov K. G., Usatyuk P., Liu F., Kaibuchi K., Verin A. D. (2004) Microtubule disassembly induces cytoskeletal remodeling and lung vascular barrier dysfunction: Role of Rho-dependent mechanisms. Journal of Cellular Physiology 201: 55-70.
8. Biswas P. S., Gupta S., Chang E., Song L., Stirzaker R. A., Liao J. K., Pernis A. B. (2010) Phosphorylation of IRF4 by ROCK2 regulates IL-17 and IL-21 production and the development of autoimmunity in mice. The Journal of Clinical Investigation 120: 3280-3295.
9. Boomkamp S. D., Riehle M. O., Wood J., Olson M. F., & Barnett S. C. (2012) The development of a rat in vitro model of spinal cord injury demonstrating the additive effects of Rho and ROCK inhibitors on neurite outgrowth and myelination. Glia 60: 441-456.
10. Breitenlechner C., Gassel M., Hidaka H., Kinzel V., Huber R., Engh R.A.,Bossemeyer D. (2003) Protein kinase A in complex with Rho-kinase inhibitors Y-27632, Fasudil, and H-1152P: Structural basis of selectivity. Structure 11: 1595-1607.
11. Brown R. A., Narayanan S., & Arnold D. L. (2012) Segmentation of magnetization transfer ratio lesions for longitudinal analysis of demyelination and remyelination in multiple sclerosis. NeuroImage 66C: 103-109.
12. Bruck W., Bitsch A., Kolenda H., Bruck Y., Stiefel M., Lassmann H. (1997) Inflammatory central nervous system demyelination: Correlation of magnetic resonance imaging findings with lesion pathology. Annals of Neurology 42: 783-793.
13. Bruck W., Kuhlmann T., & Stadelmann C. (2003) Remyelination in multiple sclerosis. Journal of the Neurological Sciences 206: 181-185.
14. Calaora V., Rogister B., Bismuth K., Murray K., Brandt H., Leprince P.,Dubois-Dalcq M. (2001) Neuregulin signaling regulates neural precursor growth and the generation of oligodendrocytes in vitro. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience 21: 4740-4751.
15. Cammer W. (1999) The neurotoxicant, cuprizone, retards the differentiation of oligodendrocytes in vitro. Journal of the Neurological Sciences 168: 116-120.
16. Chang A., Nishiyama A., Peterson J., Prineas J., & Trapp B. D. (2000) NG2-positive oligodendrocyte progenitor cells in adult human brain and multiple sclerosis lesions. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience 20: 6404-6412.
17. Chang Y. W., Bean R. R., & Jakobi R. (2009) Targeting RhoA/Rho kinase and p21-activated kinase signaling to prevent cancer development and progression. Recent Patents on Anti-Cancer Drug Discovery 4: 110-124.
18. Chen L., Qu G., Zhang C., Zhang S., He J., Sang N., Liu S. (2013) Quantum dots (QDs) restrain human cervical carcinoma HeLa cell proliferation through inhibition of the ROCK-c-Myc signaling. Integrative Biology: Quantitative Biosciences from Nano to Macro 5: 590-596.
19. Chen M., Liu A., Ouyang Y., Huang Y., Chao X., Pi R. (2013) Fasudil and its analogs: A new powerful weapon in the long war against central nervous system disorders? Expert Opinion on Investigational Drugs 22: 537-550.
20. Chojnacki A., & Weiss S. (2004) Isolation of a novel plateletderived growth factor-responsive precursor from the embryonic ventral forebrain. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience 24: 10888-10899.
21. Chojnacki A., & Weiss S. (2008) Production of neurons, astrocytes and oligodendrocytes from mammalian CNS stem cells. Nature Protocols 3: 935-940.
22. Chrzanowska-Wodnicka M., & Burridge K. (1996) Rho-stimulated contractility drives the formation of stress fibers and focal adhesions. The Journal of Cell Biology 133: 1403-1415.
23. Chun K. H., Araki K., Jee Y., Lee D. H., Oh B. C., Huang H., Kim Y. B. (2012) Regulation of glucose transport by ROCK1 differs from that of ROCK2 and is controlled by actin polymerization. Endocrinology 153: 1649-1662.
24. Czepiel M., Balasubramaniyan V., Schaafsma W., Stancic M., Mikkers H., Huisman C., Copray S. (2011) Differentiation of induced pluripotent stem cells into functional oligodendrocytes. Glia 59: 882-892.
25. Davies S. P., Reddy H., Caivano M., & Cohen P. (2000) Specificity and mechanism of action of some commonly used protein kinase inhibitors. The Biochemical Journal 351: 95-105.
26. Deshmukh V. A., Tardif V., Lyssiotis C. A., Green C. C., Kerman B., Kim H. J., Lairson L. L. (2013) A regenerative approach to the treatment of multiple sclerosis. Nature 502: 327-332.
27. Dincman T. A., Beare J. E., Ohri S. S., & Whittemore S. R. (2012) Isolation of cortical mouse oligodendrocyte precursor cells. Journal of Neuroscience Methods 209: 219-226.
28. Dong M., Yan B. P., & Yu C. M. (2009) Current status of rhoassociated kinases (ROCKs) in coronary atherosclerosis and vasospasm. Cardiovascular & Hematological Agents in Medicinal Chemistry 7: 322-330.
29. Duddy M., Haghikia A., Cocco E., Eggers C., Drulovic J., Carmona O., Gold R. (2011) Managing MS in a changing treatment landscape. Journal of Neurology 258: 728-739.
30. Dugas J. C., Ibrahim A., & Barres B. A. (2007) A crucial role for p57(Kip2) in the intracellular timer that controls oligodendrocyte differentiation. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience 27: 6185-6196.
31. Duong-Quy S., Beim Y., Lium Z., & Dinh-Xuanm A. T. (2013) Role of Rho-kinase and its inhibitors in pulmonary hypertension. Pharmacology & Therapeutics 137: 352-364.
32. Erickson B. J. (2008) Imaging of remyelination and neuronal health. Current Topics in Microbiology and Immunology 318: 73-92.
33. Fox R. J., Cronin T., Lin J., Wang X., Sakaie K., Ontaneda D., Phillips M. D. (2011) Measuring myelin repair and axonal loss with diffusion tensor imaging. AJNR American Journal of Neuroradiology 32: 85-91.
34. Franklin R. J., ffrench-Constant C., Edgar J. M., & Smith K. J. (2012) Neuroprotection and repair in multiple sclerosis. Nature Reviews Neurology 8: 624-634.
35. Gabrielsson J., Green A. R, & Van der Graaf P. H. (2010) Optimising in vivo pharmacology studies-Practical PKPD considerations. Journal of Pharmacological and Toxicological Methods 61: 146-156.
36. Goodman K. B., Cui H., Dowdell S. E., Gaitanopoulos D. E., Ivy R. L., Sehon C. A., Lee D. (2007) Development of dihydropyridone indazole amides as selective Rho-kinase inhibitors. Journal of Medicinal Chemistry 50: 6-9.
37. Hagemeier K., Bruck W., & Kuhlmann T. (2012) Multiple sclerosis-Remyelination failure as a cause of disease progression. Histology and Histopathology 27: 277-287.
38. Hahmann C., & Schroeter T. (2010) Rho-kinase inhibitors as therapeutics: From pan inhibition to isoform selectivity. Cellular and Molecular Life Sciences: CMLS 67: 171-177.
39. Hanafy K. A., & Sloane J. A. (2011) Regulation of remyelination in multiple sclerosis. FEBS Letters 585: 3821-3828.
40. Henderson A. J., Hadden M., Guo C., Douglas N., Decornez H., Hellberg M. R., Patil R. (2010) 2,3-Diaminopyrazines as Rho kinase inhibitors. Bioorganic & Medicinal Chemistry Letters 20: 1137-1140.
41. Hirooka Y., & Shimokawa H. (2005) Therapeutic potential of Rhokinase inhibitors in cardiovascular diseases. American Journal of Cardiovascular Drugs: Drugs, Devices, and Other Interventions 5: 31-39.
42. Ishikura S., Koshkina A., & Klip A. (2008) Small G proteins in insulin action: Rab and Rho families at the crossroads of signal transduction and GLUT4 vesicle traffic. Acta Physiologica 192: 61-74.
43. Izrael M., Zhang P., Kaufman R., Shinder V., Ella R., Amit M., Revel M. (2007) Human oligodendrocytes derived from embryonic stem cells: Effect of noggin on phenotypic differentiation in vitro and on myelination in vivo. Molecular and Cellular Neurosciences 34: 310-323.
44. Jepson S., Vought B., Gross C. H., Gan L., Austen D., Frantz J. D., Krauss R. (2012) LINGO-1, a transmembrane signaling protein, inhibits oligodendrocyte differentiation and myelination through intercellular self-interactions. The Journal of Biological Chemistry 287: 22184-22195.
45. Jiang B. H., Tawara S., Abe K., Takaki A., Fukumoto Y., Shimokawa H. (2007) Acute vasodilator effect of fasudil, a Rho-kinase inhibitor, in monocrotaline-induced pulmonary hypertension in rats. Journal of Cardiovascular Pharmacology 49: 85-89.
46. Jung-Testas I., Schumacher M., Robel P., & Baulieu E. E. (1996) The neurosteroid progesterone increases the expression of myelin proteins (MBP and CNPase) in rat oligodendrocytes in primary culture. Cellular and Molecular Neurobiology 16: 439-443.
47. Keirstead H. S., & Blakemore W. F. (1999) The role of oligodendrocytes and oligodendrocyte progenitors in CNS remyelination. Advances in Experimental Medicine and Biology 468: 183-197.
48. Keough M. B., & Yong V. W. (2013) Remyelination therapy for multiple sclerosis. Neurotherapeutics: The Journal of the American Society for Experimental NeuroTherapeutics 10: 44-54.
49. Kipp M., Victor M., Martino G., & Franklin R. J. (2012) Endogeneous remyelination: Findings in human studies. CNS & Neurological Disorders Drug Targets 11: 598-609.
50. Kippert A., Fitzner D., Helenius J., & Simons M. (2009) Actomyosin contractility controls cell surface area of oligodendrocytes. BMC Cell Biology 10: 71.
51. Konola L. T., Tyler B. M., Yamamura T., & Lees M. B. (1991) Distribution of proteolipid protein and myelin basic protein in cultured mouse oligodendrocytes: Primary vs. secondary cul-tures. Journal of Neuroscience Research 28: 49-64.
52. Kornblum H. I., Yanni D. S., Easterday M. C., & Seroogy K. B. (2000) Expression of the EGF receptor family members ErbB2, ErbB3, and ErbB4 in germinal zones of the developing brain and in neurosphere cultures containing CNS stem cells. Developmental Neuroscience 22: 16-24.
53. Koyanagi M., Takahashi J., Arakawa Y., Doi D., Fukuda H., Hayashi H., Hashimoto N. (2008) Inhibition of the Rho/ ROCK pathway reduces apoptosis during transplantation of embryonic stem cell-derived neural precursors. Journal of Neuroscience Research 86: 270-280.
54. Lachyankar M. B., Condon P. J., Quesenberry P. J., Litofsky N. S., Recht L. D, Ross A. H. (1997) Embryonic precursor cells that express Trk receptors: Induction of different cell fates by NGF, BDNF, NT-3, and CNTF. Experimental Neurology 144: 350-360.
55. Li Y., Gautam A., Yang J., Qiu L., Melkoumian Z., Weber J.,Brandenberger R. (2013) Differentiation of oligodendrocyte progenitor cells from human embryonic stem cells on vitronectin-derived synthetic peptide acrylate surface. Stem Cells and Development 22: 1497-1505.
56. Liao J. K., Seto M., & Noma K. (2007) Rho kinase (ROCK) inhibitors. Journal of Cardiovascular Pharmacology 50: 17-24.
57. McCarthy K. D., & de Vellis J. (1980) Preparation of separate astroglial and oligodendroglial cell cultures from rat cerebral tissue. The Journal of Cell Biology 85: 890-902.
58. Medina-Rodriguez E. M., Arenzana F. J., Pastor J., Redondo M., Palomo V., Garcia de Sola R., de Castro F. (2013) Inhibition of endogenous phosphodiesterase 7 promotes oligodendrocyte precursor differentiation and survival. Cellular and Molecular Life Sciences: CMLS 70: 3449-3462.
59. Melendez-Vasquez C. V., Einheber S., & Salzer J. L. (2004) Rho kinase regulates schwann cell myelination and formation of associated axonal domains. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience 24: 3953-3963.
60. Miron V. E., Rajasekharan S., Jarjour A. A., Zamvil S. S., Kennedy T. E., Antel J. P. (2007) Simvastatin regulates oligodendroglial process dynamics and survival. Glia 55: 130-143.
61. Monaco, M. C., Maric, D., Bandeian, A., Leibovitch, E., Yang, W., & Major, E. O. (2012). Progenitor-derived oligodendrocyte culture system from human fetal brain. Journal of Visualized Experiments: JoVE, 70, e4274.
62. Mueller B. K, Mack H., & Teusch N. (2005) Rho kinase, a promising drug target for neurological disorders. Nature Reviews Drug Discovery 4: 387-398.
63. Mullins R. D., Heuser J. A., & Pollard T. D. (1998) The interaction of Arp2/3 complex with actin: Nucleation, high affinity pointed end capping, and formation of branching networks of filaments. Proceedings of the National Academy of Sciences of the United States of America 95: 6181-6186.
64. Nakagawa O., Fujisawa K., Ishizaki T., Saito Y., Nakao K, Narumiya S. (1996) ROCK-I and ROCK-II, two isoforms of Rho-associated coiled-coil forming protein serine/threonine kinase in mice. FEBS Letters 392: 189-193.
65. Nakahara J., Maeda M., Aiso S., & Suzuki N. (2012) Current concepts in multiple sclerosis: Autoimmunity versus oligodendrogliopathy. Clinical Reviews in Allergy & Immunology 42: 26-34.
66. Narumiya S., Ishizaki T., & Uehata M. (2000) Use and properties of ROCK-specific inhibitor Y-27632. Methods in Enzymology 325: 273-284.
67. Nichols R. J., Dzamko N, Hutti J. E., Cantley L. C, Deak M., Moran J., Alessi D. R. (2009) Substrate specificity and inhibitors of LRRK2, a protein kinase mutated in Parkinson's disease. The Biochemical Journal 424: 47-60.
68. Ogawa S., Tokumoto Y., Miyake J., & Nagamune T. (2011) Induction of oligodendrocyte differentiation from adult human fibroblast-derived induced pluripotent stem cells. In Vitro Cellular & Developmental Biology Animal 47: 464-469.
69. Olson M. F. (2008) Applications for ROCK kinase inhibition. Current Opinion in Cell Biology 20: 242-248.
70. Paintlia A. S., Paintlia M. K., Khan M., Vollmer T., Singh A. K, Singh I. (2005) HMG-CoA reductase inhibitor augments survival and differentiation of oligodendrocyte progenitors in animal model of multiple sclerosis. FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology 19: 1407-1421.
71. Paintlia A. S., Paintlia M. K, Singh A. K, & Singh I. (2008) Inhibition of rho family functions by lovastatin promotes myelin repair in ameliorating experimental autoimmune encephalomyelitis. Molecular Pharmacology 73: 1381-1393.
72. Paweletz C. P., Andersen J. N., Pollock R., Nagashima K, Hayashi M. L., Yu S. U., Chi A. (2011) Identification of direct target engagement biomarkers for kinase-targeted therapeutics. PloS One 6: e26459.
73. Pedraza C. E., Monk R., Lei J., Hao Q., & Macklin W. B. (2008) Production, characterization, and efficient transfection of highly pure oligodendrocyte precursor cultures from mouse embryonic neural progenitors. Glia 56: 1339-1352.
74. Raad M., El Tal T., Gul R., Mondello S., Zhang Z., Boustany R. M., Kobeissy F. (2012) Neuroproteomics approach and neurosystems biology analysis: ROCK inhibitors as promising therapeutic targets in neurodegeneration and neurotrauma. Electrophoresis 33: 3659-3668.
75. Rao M. S. (1999) Multipotent and restricted precursors in the central nervous system. The Anatomical Record 257: 137-148.
76. Ridley A. J. (2001) Rho family proteins: Coordinating cell responses. Trends in Cell Biology 11: 471-477.
77. Ridley A. J., Schwartz M. A., Burridge K, Firtel R. A., Ginsberg M. H., Borisy G., Horwitz A. R. (2003) Cell migration: Integrating signals from front to back. Science 302: 1704-1709.
78. Rikitake Y., Oyama N., Wang C. Y., Noma K, Satoh M., Kim H. H., Liao J. K. (2005) Decreased perivascular fibrosis but not cardiac hypertrophy in ROCK1+/- haploinsufficient mice. Circulation 112: 2959-2965.
79. Ryan T., Shelton M., Lambert J. P., Malecova B., Boisvenue S., Ruel M., Skerjanc I. S. (2013) Myosin phosphatase modulates the cardiac cell fate by regulating the subcellular localization of Nkx2.5 in a Wnt/Rho-associated protein kinasedependent pathway. Circulation Research 112: 257-266.
80. Satoh S., Takayasu M., Kawasaki K., Ikegaki I., Hitomi A., Yano K., Asano T. (2012) Antivasospastic effects of hydroxyfasudil, a Rho-kinase inhibitor, after subarachnoid hemorrhage. Journal of Pharmacological Sciences 118: 92-98.
81. Schmidt F., van den Eijnden M., Pescini Gobert R., Saborio G. P., Carboni S., Alliod C., Hooft van Huijsduijnen R. (2012) Identification of VHY/Dusp15 as a regulator of oligodendrocyte differentiation through a systematic genomics approach. PloS One 7: e40457.
82. Schofield A. V., & Bernard O. (2013) Rho-associated coiled-coil kinase (ROCK) signaling and disease. Critical Reviews in Biochemistry and Molecular Biology 48: 301-316.
83. Sehon C. A., Wang G. Z., Viet A. Q., Goodman K. B., Dowdell S. E., Elkins P. A., Lee D. (2008) Potent, selective and orally bioavailable dihydropyrimidine inhibitors of Rho kinase (ROCK1) as potential therapeutic agents for cardiovascular diseases. Journal of Medicinal Chemistry 51: 6631-6634.
84. Shi J., & Wei L. (2013) Rho kinases in cardiovascular physiology and pathophysiology: The effect of fasudil. Journal of Cardiovascular Pharmacology 62: 341-354.
85. Somlyo A. P., & Somlyo A. V. (2000) Signal transduction by G-proteins, rho-kinase and protein phosphatase to smooth muscle and non-muscle myosin II. The Journal of Physiology 522(Pt 2): 177-185.
86. Song J., Goetz B. D., Baas P. W., & Duncan I. D. (2001) Cytoskeletal reorganization during the formation of oligodendrocyte processes and branches. Molecular and Cellular Neurosciences 17: 624-636.
87. Staugaitis S. M., Chang A., & Trapp B. D. (2012) Cortical pathology in multiple sclerosis: Experimental approaches to studies on the mechanisms of demyelination and remyelination. Acta Neurologica Scandinavica Supplementum 195: 97-102.
88. Stroet A., Linker R. A., & Gold R. (2013) Advancing therapeutic options in multiple sclerosis with neuroprotective properties. Journal of Neural Transmission 120(Suppl 1): S49-S53.
89. Sun X., Minohara M., Kikuchi H., Ishizu T., Tanaka M., Piao H., Kira J. (2006) The selective Rho-kinase inhibitor fasudil is protective and therapeutic in experimental autoimmune encephalomyelitis. Journal of Neuroimmunology 180: 126-134.
90. Svitkina T. M., & Borisy G. G. (1999) Arp2/3 complex and actin depolymerizing factor/cofilin in dendritic organization and treadmilling of actin filament array in lamellipodia. The Journal of Cell Biology 145: 1009-1026.
91. Svitkina T. M., Bulanova E. A., Chaga O. Y., Vignjevic D. M., Kojima S., Vasiliev J. M., Borisy G. G. (2003) Mechanism of filopodia initiation by reorganization of a dendritic network. The Journal of Cell Biology 160: 409-421.
92. Sward K., Dreja K., Susnjar M., Hellstrand P., Hartshorne D. J., Walsh M. P. (2000) Inhibition of Rho-associated kinase blocks agonist-induced Ca2{thorn} sensitization of myosin phosphorylation and force in guinea-pig ileum. The Journal of Physiology 522(Pt. 1): 33-49.
93. Tamura M., Nakao H., Yoshizaki H., Shiratsuchi M., Shigyo H., Yamada H., Hidaka H. (2005) Development of specific Rhokinase inhibitors and their clinical application. Biochimica Et Biophysica Acta 1754: 245-252.
94. Thumkeo D., Shimizu Y., Sakamoto S., Yamada S., & Narumiya S. (2005) ROCK-I and ROCK-II cooperatively regulate closure of eyelid and ventral body wall in mouse embryo. Genes to Cells: Devoted to Molecular & Cellular Mechanisms 10: 825-834.
95. Tojkander S., Gateva G., & Lappalainen P. (2012) Actin stress fibers-Assembly, dynamics and biological roles. Journal of Cell Science 125: 1855-1864.
96. Tropepe V., Sibilia M., Ciruna B. G., Rossant J., Wagner E. F., van der Kooy D. (1999) Distinct neural stem cells proliferate in response to EGF and FGF in the developing mouse telencephalon. Developmental Biology 208: 166-188.
97. Tsai M. H., & Jiang M. J. (2006) Rho-kinase-mediated regulation of receptor-agonist-stimulated smooth muscle contraction. Pflügers Archiv: European Journal of Physiology 453: 223-232.
98. Velasco G., Armstrong C., Morrice N., Frame S., & Cohen P. (2002) Phosphorylation of the regulatory subunit of smooth muscle protein phosphatase 1M at Thr850 induces its dissociation from myosin. FEBS Letters 527: 101-104.
99. Wang H., Rusielewicz T., Tewari A., Leitman E. M., Einheber S., Melendez-Vasquez C. V. (2012) Myosin II is a negative regu-lator of oligodendrocyte morphological differentiation. Journal of Neuroscience Research 90: 1547-1556.
100. Wang H., Tewari A., Einheber S., Salzer J. L., & Melendez-Vasquez C. V. (2008) Myosin II has distinct functions in PNS and CNS myelin sheath formation. The Journal of Cell Biology 182: 1171-1184.
101. Wolswijk G. (2002) Oligodendrocyte precursor cells in the demye-linated multiple sclerosis spinal cord. Brain: A Journal of Neurology 125: 338-349.
102. Xiao L., Guo D., Hu C., Shen W., Shan L., Li C., He C. (2012) Diosgenin promotes oligodendrocyte progenitor cell differentiation through estrogen receptor-mediated ERK1/2 activation to accelerate remyelination. Glia 60: 1037-1052.
103. Yang N., Higuchi O., Ohashi K., Nagata K., Wada A., Kangawa K., Mizuno K. (1998) Cofilin phosphorylation by LIM-kinase 1 and its role in Rac-mediated actin reorganization. Nature 393: 809-812.
104. Yu J. Z., Ding J., Ma C. G., Sun C. H., Sun Y. F., Lu C. Z., Xiao B. G. (2010) Therapeutic potential of experimental autoimmune encephalomyelitis by fasudil, a Rho kinase inhibitor. Journal of Neuroscience Research 88: 1664-1672.
105. Zhang, C., Zhang, S., Zhang, Z., He, J., Xu, Y., & Liu, S. (2013). ROCK has a crucial role in regulating prostate tumor growth through interaction with c-Myc. Oncogene. Advance online publication. doi:10.1038/onc.2013.505.
106. Zhornitsky S., Wee Yong V., Koch M. W., Mackie A., Potvin S., Patten S. B., Metz L. M. (2013) Quetiapine fumarate for the treatment of multiple sclerosis: Focus on myelin repair. CNS Neuroscience & Therapeutics 19: 737-744.
107. Zhou F. C., & Chiang Y. H. (1998) Long-term nonpassaged EGF-responsive neural precursor cells are stem cells. Wound Repair and Regeneration: Official Publication of the Wound Healing Society [and] the European Tissue Repair Society 6: 337-348.
108. Zuchero J. B., & Barres B. A. (2013) Intrinsic and extrinsic control of oligodendrocyte development. Current Opinion in Neurobiology 23: 914-920.